Spinal Muscular Atrophy Treatment Market Size

Spinal Muscular Atrophy Treatment Market size was over USD 8.9 billion in 2024 and is estimated to reach USD 73.9 billion by the end of 2037, expanding at a CAGR of 19.3% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of the market is projected to be valued at USD 10.6 billion. According to the National Library of Medicine, in October 2023, the incidence of SMA is estimated at 1 in 6000–10,000, with a carrier frequency of 1/40–1/60. Even though spinal muscular atrophy is considered a rare disease, the rising incidence of the cases, especially among newborn children is anticipated to boost the spinal muscular atrophy treatment market during the forecast period.

The growing prevalence of the genetic disorder has led to a rising awareness and demand for early diagnosis. Advances in gene therapies, and increasing investments in R&D, particularly in RNA-based therapies, have propelled the demand for novel, effective treatments. Governments and healthcare organizations are also playing a crucial role by providing incentives and fast-tracking drug approvals for rare diseases. Personalized medicine approaches, aim to improve patient outcomes by tailoring treatments to specific genetic profiles. Collaborations between biotech firms and academic institutions are further accelerating drug discovery, while patient advocacy groups are raising awareness and driving demand for innovative therapies in the spinal muscular atrophy treatment market.